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Abstract
Progranulin deficiency is thought to cause some forms of frontotemporal dementia (FTD), a major early-onset age-
dependent neurodegenerative disease. How progranulin (PGRN) expression is regulated is largely unknown. We identified
an evolutionarily conserved binding site for microRNA-29b (miR-29b) in the 39 untranslated region (39UTR) of the human
PGRN (hPGRN) mRNA. miR-29b downregulates the expression of luciferase through hPGRN or mouse PGRN (mPGRN)
39UTRs, and the regulation was abolished by mutations in the miR-29b binding site. To examine the direct effect of
manipulating endogenous miR-29b on hPGRN expression, we established a stable NIH3T3 cell line that expresses hPGRN
under the control of the cytomegalovirus promoter. Ectopic expression of miR-29b decreased hPGRN expression at the both
mRNA and protein levels. Conversely, knockdown of endogenous miR-29b with locked nucleic acid increased the
production and secretion of hPGRN in NIH3T3 cells. Endogenous hPGRN in HEK 293 cells was also regulated by miR-29b.
These findings identify miR-29b as a novel posttranscriptional regulator of PGRN expression, raising the possibility that miR-
29b or other miRNAs might be targeted therapeutically to increase hPGRN levels in some FTD patients.
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Introduction
Frontotemporal dementia (FTD) is associated with focal atrophy
in the frontal and/or temporal lobes that alters personality and
social behaviors and impairs language and cognition, among other
clinical manifestations [1]. FTD is now recognized as the most
common cause of early onset dementia in people under the age of
60, but effective treatment is still unavailable [2]. In addition to
pathogenic mutations in TAU [3,4], several disease genes have
been identified that offer great hope for elucidating the pathogenic
mechanisms of FTD and developing therapeutic approaches.
These genes encode the AAA-type ATPase valosin-containing
protein [5], the endosomal sorting complex required for transport
III (ESCRT-III) component CHMP2B [6], and a secreted
glycoprotein called progranulin [7,8]. In addition, two RNA-
binding proteins, TDP-43 [9,10] and FUS [11,12], have been
identified in subsets of FTD brains as major ubiquitylated proteins
in tau-negative cytoplasmic inclusions.
Among these pathogenic factors, progranulin stands out with
two unique features. First, encoded by the GRN gene, it is the only
secreted protein [13]. Second, the underlying mechanism of FTD
associated with progranulin mutations is thought to be haploin-
sufficiency [7,8], whereas other disease proteins seem to contribute
to pathogenesis, at least in part, through toxic gain-of-function
mechanisms [14–17]. Thus, molecular interventions that increase
the production and secretion of progranulin from the remaining
wildtype GRN allele are potential therapeutic strategies. In
principle, progranulin expression and secretion in neurons or
other cell types in the brain could be regulated by multiple
mechanisms—none of which have been extensively investigated.
MicroRNAs (miRNAs) are small, noncoding RNAs that
regulate gene expression mostly by binding to the 39 untranslated
region (39UTR) of target mRNAs [18,19]. Typically 21–23
nucleotides long, miRNAs repress translation or decrease the
stability of their target mRNAs [18–20]. Some miRNAs evidently
upregulate the expression of their target mRNAs by binding to
59UTRs or coding regions [21,22]. miRNAs are involved in gene
expression in a wide range of cellular and developmental contexts,
including the nervous system [23–25]. Although the human
genome has 500 or more miRNAs, each predicted to target
hundreds of mRNAs [18–20], few miRNA–target interactions
have been validated experimentally. Because of their small size,
miRNAs and their target sites are becoming attractive candidates
for developing potential therapeutic approaches for human
diseases [26].
In this study, we identified a miR-29b binding site in the 39UTR
of hPGRN mRNA. Both overexpression and locked nucleic acid
(LNA) knockdown experiments demonstrated a role for miR-29b
in regulating progranulin expression through its 39UTR. Increased
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progranulin translation led to increased secretion. Thus, miR-29b
is novel regulator of progranulin expression, raising the possibility
of manipulating the activities of miR-29b and other miRNAs in
the adult brain to treat FTD associated with progranulin
deficiency.
Results
The 39UTR of hPGRN mRNA Contains a Predicted miR-
29b Binding Site
It remains challenging to use computational approaches to
systematically and accurately predict the genome-wide targets of
each miRNA and potential miRNAs that regulate a specific
mRNA under physiological conditions [27]. To identify miRNAs
that regulate hPGRN expression, we used an miRNA target
prediction program that considers complementarity, target site
accessibility, and the extent of evolutionary conservation [28].
This program predicted a putative binding site for miR-29b in the
hPGRN 39UTR, which contains about 300 nucleotides (Fig. 1A,
B). MiR-29b is highly conserved in vertebrates, and its nucleotide
sequence is 100% identical among several species (Fig. 1C).
Although 39UTR sequences tend to drift more rapidly during
evolution [27], the putative binding sites for miR-29b in PGRN
39UTRs are also highly conserved in mammals, with only one
nucleotide difference between humans and rodents (Fig. 1D),
suggesting an evolutionarily conserved miRNA–mRNA interac-
tion with potentially important regulatory functions. Moreover,
miR-29b is highly expressed in adult brains and in postmitotic
neurons [29]. This expression pattern overlaps with that of
progranulin [30]. Thus, miR-29b is a good candidate miRNA that
may directly regulate progranulin expression. The following
studies were intended to address this question in detail.
miR-29b Suppresses Expression of the Luciferase
Reporter Containing the hPGRN 39UTR
To validate the interaction between miR-29b and the hPGRN
39UTR, we cloned hPGRN 39UTR into the reporter vector to
serve as the 39UTR of the luciferase coding region (Fig. 2A). We
also cloned the 421-nucleotide genomic fragment that contains
pre-miR-29b-1 into the pSuper vector (Fig. 2A). Cotransfection of
these two vectors into HEK293 cells decreased luciferase
expression to a greater extent than a control vector that lacked
miRNAs (Fig. 2B). Cotransfection of miR-29b-1 and the luciferase
vector without hPGRN 39UTR did not affect luciferase expression
(data not shown). Thus, miR-29b-1 acts through hPGRN 39UTR
to regulate luciferase expression.
Mature miR-29b can be produced from two precursors encoded
by two genes located on chromosomes 7 and 1, respectively.
Expression of pre-miR-29b-1 or pre-miR-29b-2 suppressed the
expression of luciferase with hPGRN 39UTR (Fig. 2B), suggesting
that both genes indeed can produce functional mature miR-29b to
regulate hPGRN 39UTR. No suppression was seen after
cotransfection with a negative control vector expressing miR-9
[31], which has no predicted binding site in hPGRN mRNA
(Fig. 2C). Since hPGRN and mPGRN mRNAs contain conserved
binding sites for miR-29b (Fig. 1D), and the effects of miRNAs
depend on the secondary structures of surrounding mRNA
sequences, we also examined whether miR-29b could also interact
with mPGRN mRNA. We cloned mPGRN 39UTR into the
luciferase reporter construct and found that indeed miR-29b also
suppressed luciferase expression through mPGRN 39UTR
(Fig. 2C).
In addition to vector-based expression of pre-miR-29b-1, which
produces mature miR-29b after being transfected into HEK293
cells, we also used miRNA mimics, which are double-stranded
RNA oligonucleotides that are chemically modified with Dhar-
macon ON-TARGET (Themo Scientific Dharmacon). Transfec-
tion of miR-29b but not miR-9 mimics decreased luciferase
reporter expression (Fig. 2D). For this experiment, mimics for cel-
miR-67, which does exist in mammals, were used as the control.
These findings raise the possibility that miR-29b may specifically
interact with hPGRN 39UTR.
miR-29b Directly Interacts with the Predicted Binding Site
in the hPGRN 39UTR
To examine whether the interaction between miR-29b and
hPGRN 39UTR is direct or indirect, we generated mutations in
miR-29b. In pre-miR-29b-1, we mutated two nucleotides in the
Figure 1. Identification of a miR-29b target site in the 39UTR of hPGRN mRNA. (A) Schematic representation of hPGRN mRNA
(NM_002087.2 showing with the predicted miR-29b binding site in the 39UTR. (B) The actual nucleotide sequences in hPGRN mRNA and miR-29b
show partial match. (C) Sequence alignment indicates that miR-29b is 100% conserved in vertebrates. (D) The predicted miR-29b binding site in
hPGRN 39UTR is highly conserved in mammals. The miR-29b seed sequences and their predicted binding sites in the hPGRN 39UTR are shown
underlined. The conserved nucleotides are in grey.
doi:10.1371/journal.pone.0010551.g001
MicroRNA Regulates Progranulin
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10551
miR-29b seed region from CC to GG (Fig. 3A). To ensure that
mutant pre-miR-29b-1 maintains its stem loop structure so that it
can be properly processed to produce mature miR-29b, we also
mutated GG in the opposite strand of the stem into CC (Fig. 3A).
Cotransfection of normal but not the mutant pre-miR-29b-1
suppressed luciferase reporter expression (Fig. 3B). Moreover, we
also mutated the miR-29b binding site in hPGRN 39UTR in
which GTG was changed to ACA (Fig. 3C). With such mutations
present in hPGRN 39UTR, luciferase expression failed to be
regulated by miR-29b produced from the vector expressing its
precursor (Fig. 3D). Moreover, miR-29b mimics were unable to
suppress luciferase expression with a different mutant hPGRN
39UTR in which GTG in the miR-29b binding site was mutated
to CAC (Fig. 3C, D). These experiments demonstrate that miR-
29b interacts directly with the binding site in hPGRN 39UTR to
regulate luciferase reporter expression.
miR-29b Suppresses the Production and Secretion of
hPGRN
Next, we examined the regulation of endogenous hPGRN by
miR-29b. First, to more specifically investigate the regulation of
hPGRN expression at the posttranscriptional level, we cloned
hPGRN with its full 39UTR into the pcDNA3.1(2) vector, in
which hPGRN is under the control of the pCMV promoter. We
transfected this plasmid into NIH3T3 cells and established stable
cell lines (hPGRN-3T3) in which constitutive hPGRN expression
was relatively constant, enabling greater sensitivity for detecting
miRNA-induced changes in expression at the post transcriptional
level.
Transfection of hPGRN-3T3 cells with the pre-miR-29b-1
vector significantly increased the level of mature miR-29b (Fig. 4A).
Correspondingly, the level of intracellular hPGRN as detected on
western blot was decreased by about 35% (Fig. 4B, C). Although
NIH3T3 cells also express PGRN, the antibody we used
recognized transfected hPGRN but not its mouse counterpart
expressed endogenously in NIH 3T3 Cells. We repeated the
transfection experiments and measured hPGRN levels with
ELISAs. Again, miR-29b significantly reduced the level of
intracellular hPGRN in hPGRN-3T3 cells (Fig. 4D).
We also used miR-29b mimics to increase the level of mature
miR-29b (Fig. 4A). The levels of intracellular hPGRN measured
by ELISA were significantly decreased by miR-29b mimics but not
by control mimics (Fig. 5A). Since progranulin is a secreted
molecule and its reduced trophic function is thought to underlie
Figure 2. MiR-29b suppresses the expression of the luciferase reporter with hPGRN 39UTR. (A) Schematic representation of the
constructs used in the luciferase reporter assay. hPGRN 39UTR was cloned into the luciferase vector containing the SV40 promoter, which was
cotransfected with the vector encoding pre-miR-29b-1 and H1 promoter. (B) Both pre-miR-29b-1 and pre-miR-29b-2, two genes located on different
chromosomes that produce the identical mature miR-29b, had similar effects on luciferase expression. (C) Coexpression of miR-29b but not miR-9
suppressed the expression of luciferase with hPGRN 39UTR. miR-29b also suppressed the expression of luciferase with mPGRN 39UTR. (D) Luciferase
activity was also reduced by a miR-29b mimic but not by a miR-9 mimic. Cel-miR-67 (Dharmacon), which doesn’t exist in mammals, was used as the
control. Values are mean 6 SEM. **P,0.01. ***P,0.001.
doi:10.1371/journal.pone.0010551.g002
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the pathogenesis of FTD [7,8], we wondered whether miRNA
regulation of hPGRN expression also affects the level of its
secreted form. As expected, an increased level of miR-29b led to a
lower level of hPGRN in the medium (Fig. 5B), correlating with
the decreased expression in hPGRN-3T3 cells. miRNAs can
regulate gene expression through either translational suppression
or mRNA stability or both. The decrease in the level hPGRN
protein as we observed is likely due to a decrease in hPGRN
mRNA stability since we found by quantitative RT-PCR that the
level of hPGRN mRNA was also decreased by miR-29b mimics
(Figure 5C).
To examine whether miR-29b also regulates the expression of
endogenous hPGRN, we transfected the human cell line HEK293
cells with miR-29b mimics and measured the levels of intracellular
and secreted hPGRN. To ensure that we measured the changes in
hPGRN levels after the treatment with miR-29b mimics, we
changed culture medium 24 h after transfection. During our
studies, we noticed that the transcriptional regulation of
endogenous hPGRN expression in HEK293 and other cell lines
is sensitive to extracellular stimuli and different experimental
manipulations (J. Jiao, unpublished observations), thus, we
performed this experiment with a high sample number (n = 12
per treatment). Indeed, we found that indeed the expression levels
of endogenous intracellular hPGRN (Fig. 5D) and secreted
hPGRN (Fig. 5E) were decreased by miR-29b mimics.
miR-29b Knockdown Increases the Levels of Intracellular
and Secreted hPGRN
Since ectopic expression of miR-29b suppressed hPGRN
expression, we used locked nucleic acid (LNA)-mediated miRNA
silencing to determine whether loss of endogenous miR-29b
activity enhances hPGRN expression in stably transfected
hPGRN-3T3 cells. Transfection of miR-29b-specific LNA probes
reduced endogenous miR-29b levels by about 80% (Fig. 6A).
Correspondingly, the intracellular level of hPGRN increased by
about 19%, as measured by ELISA (Fig. 6B). The level of secreted
hPGRN increased to a similar extent after miR-29b knockdown
(Fig. 6B). Thus, hPGRN expression can be regulated by
manipulating the activity of endogenous miR-29b.
Discussion
About 5–10% of familial cases of FTD are caused by mutations
in GRN [2]. Many pathogenic mutations reduce hPGRN levels,
indicating a haploinsufficiency pathogenic mechanism [7,8]. In
carriers of GRN mutations, the normal allele of GRN is still
functional. Thus, molecular interventions that increase the
production and secretion of hPGRN from the normal gene are
conceivably potential therapeutic avenues. However, very little is
known about how hPGRN expression is regulated at the
transcriptional and translational levels. Here we provide multiple
Figure 3. miR-29b directly targets hPGRN 39UTR through the seed region. (A) The seed region of miR-29b and the opposite strand in the
stem-loop in the precursor were mutated. (B) HEK293FT cells were transfected with luciferase constructs and wildtype or mutant miR-29b precursors.
Luciferase activity was reduced by miR-29b but not by mutant miR-29b. (C) The seed region binding site in the hPGRN 39UTR was mutated. Two
different mutant 39UTR were generated. (D) Mutant hPGRN 39UTR did not respond to miR-29b suppression. Mutant 1 was used for experiment with
the miR-29b vector. Mutant 2 was used for experiment with the miR-29b mimic. The seed region is underlined. **P,0.01. n.s. not significant.
doi:10.1371/journal.pone.0010551.g003
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lines of experimental evidence to demonstrate that miR-29b is a
novel regulator of hPGRN production.
We identified miR-29b with a miRNA target prediction
program that takes into account the secondary structures of target
mRNAs and seed region complementarity [28]. We also
confirmed that miR-29b interacts directly with the hPGRN
39UTR and regulates the expression level of endogenous hPGRN.
An important experimental approach in this study is the use of a
stable NIH3T3 cell line that expresses hPGRN under the control
of the CMV promoter. During our study, we noticed that the level
of endogenous progranulin is very sensitive to many extracellular
stimuli, which makes it difficult to examine the specific effects of
miRNAs. The use of the stably transfected cell line allowed us to
bypass the effects of our experimental manipulation on the
transcription of endogenous progranulin and focus on the effects of
miRNAs on posttranscriptional regulation of progranulin expres-
sion with a more sensitive system. As expected, the effect of miR-
29b on progranulin expression is not as dramatic as that of
transcription factors, consistent with the notion that in many cases,
miRNAs fine tune gene expression [20,27].
MiR-29b is downregulated in several types of tumor cells
[32–34], which is in reverse correlation with the increased
progranulin expression in tumor cells [35]. Thus, the regulatory
interaction between miR-29b and hPGRN may exist during
tumorigenesis as well. In the nervous system, miR-29b is
developmentally regulated, with the highest level in adult mouse
brain [29]. Interestingly, the miR-29a/b-1 cluster is significantly
decreased in the brains of Alzheimer’s disease patients, and the
decrease correlates with the increased level of b-secretase [29].
MiR-29b regulates several other mRNA targets as well
[33,34,36,37], consistent with the notion that each miRNA targets
many mRNAs in different cellular and developmental settings
[27]. Thus, caution is needed when considering miRNAs as
potential therapeutic target. In the case of progranulin, the
potential effects of miR-29b knockdown on other mRNA targets
and biological processes must be considered. With that stated,
miRNAs are attractive potential drug targets for FTD because
antigomirs are relative small and have been used successfully in in
vivo models of cardiovascular diseases [38].
Two other miRNAs, miR-588 and miR-615-5p, were predicted
to target hPGRN mRNA by more than two target prediction
programs. miR-588 but not miR-615-5p also suppressed hPGRN
expression in stable cell lines (data not shown), indicating that
multiple miRNAs may be potential targets for therapeutic
manipulation of hPGRN levels. Indeed, miR-659 also inhibits
hPGRN expression [39]. Interestingly, a common genetic variant
(rs5848) in the binding site of miR-659 increases the inhibition of
hPGRN expression by miR-659 [39]. Thus, alterations in the
miRNA pathway may contribute to the molecular pathogenesis of
FTD, although the specific role of this genetic variant (rs5848) in
the pathogenesis of FTD remains to be clarified [39,40].
It seems certain that, in addition to miRNA regulation, the
production and secretion of hPGRN is regulated at multiple levels
by several other mechanisms. It will be important to investigate all
these molecular pathways to identify the most promising molecular
targets to increase the levels of hPGRN in patients with FTD.
Materials and Methods
Cell Culture
HEK293FT cells (Invitrogen) were maintained in Dulbecco’s
modified Eagle medium (Gibco) supplemented with 10% fetal
bovine serum. An hPGRN-expressing NIH-3T3 stable cell line
(hPGRN-3T3) was established by transfecting pcDNA3.1(2)
containing full-length hPGRN cDNA (including the 39UTR) into
NIH3T3 cells (Invitrogen) and selecting cells with G418 for 3 weeks.
DNA Constructs
The full-length 39UTRs of hPGRN and mPGRN mRNAs were
amplified from cDNAs of HEK293FT or genomic DNAs from
mouse ES cells by PCR. 59-TCTAGAGGGACAGTACTGA
AGACT-39 (forward primer) and 59-TCTAGAGAAAGTGTA-
CAAACTTT ATTG-39 (reverse primer) were used to amplify
hPGRN 39UTR and 59-TCTAGA GGAAGGGCTACA-
GACTTA-39 (forward primer) and 59-TCTAGAGAAAGTGTA
CAAACTTTATTG-39 (reverse primer) were used to amplify
mPGRN 39UTR. The primers were designed to put an XbaI
restriction enzyme site at both the 59 and 39 ends of the PCR
products, which were then subcloned into the XbaI site of the PGL3
promoter vector containing the luciferase reporter (Promega).
MiR-29b precursors were amplified from HEK293FT genomic
DNA using 59-GTCGA CCTGACTGCCATTTG-39 and 59-
ATCGA TGCTCTCCCATCAATA-39 for pre-miR-29b-1 on
chromosome 7 and 59-GTCGACT GTGTTTATTTTAAACA-
CAA-39 and 59-ATCGATTGAATCTCCCTTCT TTCTT-39
for pre-miR-29b-2 on chromosome 1. SalI and ClaI restriction
enzyme sites were placed at the ends of the PCR products for
subcloning into the pSuper basic vector (OligoEngine).
Full-length hPGRN cDNA with the 39UTR in pCMV-
SPORT6 was from Open Biosystems (Thermo Scientific). The
Figure 4. MiR-29b decreases the levels of intracellular and
secreted hPGRN. (A) The relative levels of mature miR-29b in hPGRN-
3T3 cells were increased by transient expression of the miR-29b
precursor or miR-29b mimic. (B) Western blot analysis showing that the
lower intracellular levels of hPGRN in hPGRN-3T3 cells after ectopic
expression of pre-miR-29b-1. Actin was used as the loading control. (C)
Quantification of relative intracellular hPGRN levels with or without the
overexpression of pre-miR-29b-1. n = 4. WB: western blot. (D) The
relative intracellular levels of hPGRN with or without overexpression of
pre-miR-29b-1 were also measured by ELISA.
doi:10.1371/journal.pone.0010551.g004
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Figure 5. (A, B) hPGRN-3T3 cells were transfected with miR-29b or negative control mimics, and the relative hPGRN levels in total cell lysates (A) and
medium (B) were determined by ELISA. In all cases, the relative level of the control was set as 1.0. Values are mean 6 SEM. *P,0.05. **P,0.01.
***P,0.001. (C) Quantitative RT-PCR analysis revealed that the level of hPGRN mRNA was decreased by miR-29b mimics. (D, E) The relative hPGRN
levels in total cell lysates (D) and medium (E) of HEK293 cells as determined by ELISA after transfection with miR-29b or control mimics. Value are
mean 6 SEM. ** P,0.01, *** P,0.001. n = 12.
doi:10.1371/journal.pone.0010551.g005
Figure 6. Knockdown of endogenous miR-29b led to increased production and secretion of hPGRN. (A) qRT-PCR confirmed that mature
miR-29b level was decreased by about 80% in hPGRN-3T3 cells transfected with miR-29b-specific LNA. (B) hPGRN-3T3 cells were transfected with miR-
29b-specific or scrambled LNA knockdown probes, and the hPGRN levels in total cell lysates and medium were determined by ELISA. Values are
mean 6 SEM. *P,0.05, **P,0.01. n = 4.
doi:10.1371/journal.pone.0010551.g006
MicroRNA Regulates Progranulin
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hPGRN cDNA was cloned into the pcDNA3.1(2) vector between
the EcoRI and HindIII sites.
Mutagenesis
Mutagenesis of miR-29b and its putative target site in hPGRN
39UTR was carried out with the QuickChange Multi Site-
Directed Mutagenesis kit (Stratagene) according to the manufac-
turer’s instructions. For mutagenesis of miR-29b, 59-CCCAAGA
ACACTGATTTCAAATCCTGCTAGAC AATCAC-39 and 59-
AATCTA AACCAGG ATATGAAACCAGCTTCCTGAAGAA
GC-39 were used. For mutagenesis of the miR-29b target site in
hPGRN 39UTR, 59-GACCCTGTGGCCAGACACTTTTCC
CTATCCACAG-39 was used.
Dual Luciferase Assay
HEK293FT cells were placed in 24-well plates the day before
transfection. Firefly luciferase expression vectors (PGL3; 200 ng),
miR-29b-pSuper or pSuper empty vector (200 ng), and Renilla
luciferase expression vector (50 ng) were cotransfected into the
cells with Lipofectamine 2000 (Invitrogen) following the manu-
facturer’s instructions. Luciferase assays were performed 24 or
48 h later with the Dual Luciferase Reporter Assay System
(Promega) as directed by the manufacturer. Firefly luciferase
activity was normalized to Renilla luciferase activity. The
experiments were carried out in quadruplicate.
Quantitative RT-PCR
Total RNAs were isolated from the hPGRN-3T3 stable cell line
using the miRNeasy mini kit (Qiagen) according to the
manufacturer’s instruction. Total RNAs (10 ng) was reverse
transcribed into cDNA with the TaqMan microRNA reverse
transcription kit (Applied Biosystems) with miR-29b, miR-126 or
U6 specific RT primers. The cDNAs were then used for real-time
PCR reaction with Taqman MicroRNA assay kits specific for
miR-29b, miR-126, and U6 (Applied Biosystems). miR-29b levels
were normalized to miR-126 or U6 levels.
To quantify hPGRN mRNA levels, total RNAs were isolated
from the hPGRN-3T3 stable cell line using the RNeasy mini kit
(Qiagen) according to the manufacturer’s instruction. Total RNAs
(1 ug) were reverse transcribed into cDNA with the TaqMan
reverse transcription kit (Applied Biosystems) using random
hexamers primers. The cDNAs were then used for real-time
PCR reaction with SYBR green PCR master mix (Applied
Biosystems) using hPGRN primers 59- CCTGGACCCCGGAG-
GAGC-39 and 59-ACGGTAAAGATGCAGGAGTGG-39, and
human GAPDH primers 59- TGCACCACCACCTGCTTAGC-
39 and 59- GGCATGGACTGTGGTCATGAG-39. hPGRN
levels were normalized to hGAPDH levels.
Western Blotting
Total cell lysates were prepared using RIPA buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% sodium dodecyl sulfate) with protease inhibitor
cocktail (Thermo Scientific). Protein samples were separated by
SDS-PAGE with 10% gels and transferred to polyvinylidine
fluoride (PVDF) membranes. The following antibodies were used:
rabbit polyclonal anti-hPGRN (1:1000; Alexis Biochemicals); goat
polyclonal anti-hPGRN (1:1000; R&D Systems) and mouse
monoclonal anti-actin (1:5000; Sigma).
Enzyme-linked Immunosorbent Assay (ELISA)
hPGRN-3T3 stable cells (1.26105 cells per well) were seeded in
12-well plates. The next day, the medium was changed to fresh
Dulbecco’s modified Eagle medium with 10% fetal bovine serum,
and the cells were transfected 2 h later with 100 pmol of miRNA
mimics (Dharmacon) (final concentration in the medium was
100 nM) or miRCURY LNA microRNA knockdown probes
(Exiqon) (final concentration in the medium was 100 nM), using
Lipofectamine 2000 (Invitrogen) as directed by the manufacturer.
Total cell lysates were prepared with RIPA buffer 48–72 h later,
and the medium was centrifuged at 13,000 rpm for 1 min to
remove cell debris. Total cell lysates and culture medium were
diluted 1:50 and 1:100, and hPGRN concentrations were detected
with an ELISA kit (Alexis Biochemicals) according to the
manufacturer’s instructions.
Measurement of endogenous hPGRN levels affected by
miR-29b
HEK293FT cells (1.26105 cells per well) were seeded in 12- well
plates. The next day, the medium was changed to fresh Dulbecco’s
modified Eagle medium (DMEM) with 10% fetal bovine serum
(FBS), and the cells were transfected 2 h later with 100 pmol of
control or miR-29b miRNA mimics (Dharmacon) using Lipofecta-
mine 2000 (Invitrogen) as directed by the manufacturer. The
medium was changed to fresh DMEM with 10% FBS 24 h after the
transfection, and the medium and cell lysates were collected 6 h
later. Total cell lysates were prepared with RIPA buffer, and the
medium was centrifuged at 13,000 rpm for 1 min to remove cell
debris. Total cell lysates and culture medium were diluted 1:50, and
hPGRN concentrations were detected with an ELISA kit (Alexis
Biochemicals) according to the manufacturer’s instructions.
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